Michael Hofman
@DrMHofman
Followers
4,902
Following
431
Media
770
Statuses
4,353
Working together to improve patient outcomes with personalised medicine & precision oncology: theranostics. PET/CT, prostate cancer ☢️ Prof 🇦🇺
Melbourne, Victoria
Joined December 2013
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Arsenal
• 964592 Tweets
Fenerbahçe
• 760166 Tweets
Iran
• 731891 Tweets
Milei
• 685338 Tweets
Raisi
• 527084 Tweets
Sánchez
• 336778 Tweets
Galatasaray
• 322843 Tweets
#PedroVigilaATuEsposa
• 198386 Tweets
Knicks
• 179364 Tweets
Pacers
• 135752 Tweets
Game 7
• 134227 Tweets
Ali Koç
• 92776 Tweets
الزمالك
• 85690 Tweets
#الرييس_الايراني
• 80043 Tweets
Haftaya
• 51348 Tweets
Brunson
• 50003 Tweets
Kast
• 40568 Tweets
Hart
• 39952 Tweets
Lyon
• 35947 Tweets
Militao
• 29180 Tweets
Haliburton
• 27778 Tweets
Dursun Özbek
• 22903 Tweets
#ConexiónHonduras11
• 22065 Tweets
Xander
• 17238 Tweets
ビブラスラップ
• 16503 Tweets
雨の月曜日
• 15805 Tweets
Metz
• 14252 Tweets
Bryson
• 13470 Tweets
Thibs
• 12434 Tweets
Brest
• 12192 Tweets
Rasim
• 11463 Tweets
#平野紫耀とたっぷりいこうぜ
• 10359 Tweets
#TheraP
Trial presented
#GU21
published
@TheLancet
: findings demonstrate Lu-177 PSMA-617 is a potential alternative to cabazitaxel: better activity, safety, and patient-reported outcomes
@ANZUPTrials
13
156
332
#ProPSMA
randomised study online in
@thelancet
:
PSMA PET/CT can replace CT/bone scans in men with aggressive prostate ca:
✔Accuracy 92% v 65%
✔Management impact 28% v15%
✔Uncertain findings 7% v 23%
✔Radiation dose 8 v 19mSv
@gu_onc
@pcfa
@movember
11
176
324
ENZA-P in
@TheLancetOncol
Lu-177 PSMA-617 + enzalutamide vs. enza alone:
● ↑PFS: 13.0 vs 7.8, hazard radio 0.43
● PSA90 response 78% vs 37%
● PSA50 response 93% vs. 68%
● no additional side effects
Incredible work from
@drlouiseemmett
@Prof_IanD
&
@ANZUPtrials
team
5
118
285
Another extraordinary day at
@PeterMacCC
. We gave cycle
#17
of Lu-177 PSMA-617 to a patient with prostate cancer. Continues to benefit 4+ years. Bloods and renal function normal.
Even more extraordinary, We were both wearing the same socks.
@pros_tic
14
24
254
Reading the NCCN v1.2023 prostate cancer guidelines and noting this change of wording: "Ga-68 PSMA-11 or F-18 piflufolastat PSMA PET/CT or PET/MRI are preferred for bone and soft tissue (full body) imaging.". No longer an "alternative". Now preferred.
1
66
204
"Nonmetastatic" Castration-Resistant Prostate Cancer is now officially a misnomer. New research in patients with normal CT and bone scans, show almost 100% PSMA PET+, 55% with M1 disease.
@gu_onc
9
124
196
1/
#LuTectomy
#EAU23
Game Changing Session: first use of Lu-177 PSMA-617 first-line in patients with high-risk localised N0/N1 prostate cancer: 20pt. 1-2 cycles→prostatectomy. ☢36Gy. 45% PSA50-RR. Safe. Few toxicities.
@RenuEapen
@declangmurphy
@Uroweb
4
71
198
SUVmean > 10 on PSMA PET in the Vision trial had improved OS and PFS. It's extraordinary that we found the same cut-off in our ph2
@PeterMacCC
study and
@ANZUPtrials
#TheraP
study.
**WE HAVE A NEW BIOMARKER**
#ASCO22
@ASCO
2
57
192
First we had standalone PET, then PET/CT, then PET/MRI, now PET/LINAC ... amazing technology. Biology-guided radiotherapy (BgRT).
We are officially live!
@StanfordRadOnc
is incredibly proud to deliver the first radiation treatment on a patient using the Reflexion X1 machine. Huge congratulations to our team!!
14
56
263
3
53
186
1/ Hot of the press:
#TheraP
Imaging Biomarkers presented
@asco
#GU21
. PSMA PET is a PREDICTIVE biomarker: patients randomised to Lu-PSMA-617 with very high PSMA expression on PSMA PET had a 91% PSA RESPONSE RATE (PSA decline>50%).
@ANZUPtrials
@TrialsCentre
16
70
188
Introducing the new PRIMARY score for reporting PSMA PET: using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer DIAGNOSIS.
We feel this is MAJOR advance for interpretation of PSMA PET.
@drlouiseemmett
@JournalofNucMed
5
71
185
Diagnostic Accuracy of PSMA PET/CT for Initial Staging of Intermediate to High-risk Prostate Cancer: Systematic Review and Meta-analysis
"PSMA-PET should be used as a first-line approach for the initial staging of PCa."
@EUplatinum
@declangmurphy
1
65
185
#UpFrontPSMA
: Randomised Controlled Trial using Lu-177 PSMA first-line rather than last-line in men with newly diagnosed advanced prostate cancer (hormone-sensitive). Launched today at Peter Mac. Big milestone. Thanks
@MovemberAUS
for funding this world first trial.
@AzadOncology
4
62
184
New radiotracer for clear cell renal carcinoma - CA-9 targeting peptide: SUVs >100 in tumor in first 3 patients with low background activity = WOW !!
@DebiopharmNews
@DrBenTran
@JournalofNucMed
@PeterMacRes
3
64
167
THE HISTORY OF PSMA THERANOSTICS in this months
@JournalofNucMed
I think the 2022 headline will be FDA approval of Lu-177 PSMA-617
@PCF_Science
@soulehoward1
@AndreaMiyahira
@pros_tic
2
74
162
1/ The
#ProPSMA
study was recently published in
@TheLancet
. My first tweetorial follows...
Read the full text at
@Movember
@PCFA
@gu_onc
@declangmurphy
@lawrentschuk
@SNM_MI
@ANZUPtrials
5
75
159
📢
@ANZUPtrials
#TheraP
Lu-177 PSMA-617 is an alternative to cabazitaxel for men with metastatic castration-resistant prostate cancer: less toxicity and no difference in survival.
Hot of the press:
@TheLancetOncol
7
58
159
Can SUVmax on PSMA PET/CT predict probability of clinically significant prostate cancer? It seems so ... see our analysis from the
#PRIMARY
study
@BJUIjournal
@drlouiseemmett
@nathanoverseas
@declangmurphy
@DrDanielMoon
5
51
158
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. VISION trial just published in
@NEJM
@morr316
@sartor_oliver
@DrScottTagawa
0
68
157
PSMA PET/CT (Ga-68 and F-18) will be reimbursed in Australia from 01 Jul 22 for staging intermediate-to-high risk and biochemical recurrence. Direct result of Australian led research
@PeterMacCC
@ANZUPtrials
#ARTnet
The news that patients with prostate cancer have been waiting for: PSMA PET/CT is available through MBS as at 01 July 2022 improving patient access & enabling more accurate staging of prostate cancer, leading to appropriately targeted therapies & better outcomes for patients.
0
19
49
5
43
155
First Lead-212 (Pb-212) in human images - quite remarkable that Alpha emission can be imaged with this quality.
@DrDavePattison
@AdvanCell_Iso
#PSMA
2
51
155
Is a PSMA PET/CT costly? Our health economics analysis in
#ProPSMA
revealed that it is not only more cost-effective but also more accurate than the combination of CT and bone scans ($1203 vs $1412). Plus, it offers a better patient experience! 💰📊👨⚕️
7
57
152
#TheraP
#ASCO20
: 1st RCT of Lu-177 PSMA-617 in mCRPC. Primary endpoint: 29% greater PSA>50% response rate with Lu-PSMA cf. cabazitaxel (66% vs 37%).
@ANZUPtrials
@Prof_IanD
@gu_onc
@ANSTO
@TrialsCentre
@ANSTO
@adacap_news
@MovemberAUS
@PeterMacCC
8
83
152
ViSION trial: improvements in overall survival & progression free survival with Lutetium-177 PSMA-617 ... Nice to see come through from early development to phase 3 results
@Novartis
2
62
149
#proPSMA
trial analysis demonstrates PSMA PET/CT is more accurate and CHEAPER than CT+bone scan (AU$1203 vs AU$1412). 1 scan instead of 2! Compelling evidence for widespread adoption. Online
@EUplatinum
🙏
@MovemberAUS
@PCFA
for funding.
@declangmurphy
2
52
147
PRIMARY trial results online
@EUplatinum
Multi-site, prospective
Adding PSMA to mpMRI ⬆️NPV (91% vs 72%) & sensitivity (97% vs 83%) for diagnosing clinically significant prostate cancer.
Led by
@drlouiseemmett
@DrDanielMoon
@ButeauJames
@declangmurphy
5
48
147
New paper suggesting ADT modulates PSMA uptake in normal organs: decreased salivary, liver, spleen and kidney uptake.
@JournalofNucMed
3
37
143
Quantitative PET parameters = powerful predictive (PSMA) and prognostic (FDG) biomarkers for Lu-177 PSMA therapy in prostate cancer
@TheLancetOncol
@ANZUPtrials
#TheraP
@officialEANM
@ButeauJames
@PCFA
@ANSTO
@MovemberAUS
@Prof_IanD
@drlouiseemmett
4
39
142
Arguing for the value and need for FDG PET in addition to PSMA PET to optimally select patients for Lutetium PSMA therapy
#APCCC21
@APCCC_Lugano
4
46
143
Don't miss it: 54 months follow-up of the
#ProPSMA
trial PSMA PET/CT vs CT/bone scan
Mon 13 Mar 14:15 Abstract S65
#EAU23
@Uroweb
@declangmurphy
@veerukasi
@MovemberAUS
@PCFA
@ANZUPtrials
3
43
141
LuDOTATATE vs sunitinib in pancreatic NET 1yr PFS: 80.5% vs 42%. Large difference favouring PRRT. And, much less G3/4 toxicity 44% vs 63%.
80 pt study: a lot can be achieved with small studies with effect size is large.
OCLURANDOM trial
@myESMO
🏆🏆🏆Great news ! Theragnosis is a winning therapy for NET!
@rafaelnuclear
@radioligand
@anzsnm1969
@pros_tic
@DrMHofman
@RiquemexMN
#cancer
1
6
25
2
56
140
🎉 Happy
#ClinicalTrialsDay
! We are thrilled to announce the completion of randomisation for
#UpFrontPSMA
, a major milestone in advancing research for hormone-sensitive metastatic prostate cancer with Lu-177 PSMA-617. Results 2024.
@AzadOncology
@Movember
@ANZUPtrials
@Novartis
3
40
138
First 3 patients with clear cell renal carcinoma imaged with Ga-68 DPI-4452
@PeterMacCC
: PEPTIDE targeting carbonic anhydrase 9. SUVmax in tumour over 100 in all patients (unselected). Presented today
#GU24
@ASCO
@gu_onc
@DrBenTran
@DrDarrenFeldman
@MHaskali
Next step is Lu-177
3
37
136
Actinium-225 PSMA RLT for metastatic prostate cancer in
@TheLancetOncol
Conclusion spot on: "future prospective studies investigating the safety and efficacy of 225Ac-PSMA RLT in patients who have not responded to 177Lu-PSMA RLT are needed."
2
43
134
PRIMARY: prospective multicentre trial of PSMA PET for diagnosis (not staging) of prostate cancer. Check-out our infographic -thanks
@ButeauJames
@drlouiseemmett
cannot stop:
#primary2
660pt RCT coming soon
2
55
133
Molecular Imaging of Neuroendocrine Differentiate of Prostate Cancer: Case Series. Amazing DOTATATE, PSMA & FDG PET/CT + histopathology IHC correlation. Congrats
@DrAIravani
.
@gu_onc
1
49
130
#VISION
&
#TheraP
Lu-PSMA-617 infographics! Combined results provide definitive results in men with prostate cancer who have progressed after docetaxel & androgen-receptor Rx: ⬆️OS/rPFS, low G3+ AEs, ⬆️ QoL.
@ASCO
@Novartis
@ANZUPtrials
5
54
130
Today: PSMA PET/CT funded by Medicare, enabling free access to men with prostate cancer access across Australia. Thanks to everyone who contributed to the science and policy.
@pros_tic
1
23
129
📢 LuTectomy online
@EUplatinum
📢 ✨
🔍 Findings: 🔹Effective targeted radiation 🔹Minimal side effects & surgical safety 🔹Potential new chapter in neoadjuvant therapy for HRCaP?
🔗
🍾
@RenuEapen
@declangmurphy
💰
@Movember
5
42
128
I'm concerned about twice-weekly RATs in Melbourne schools. Once immunity is gained (vaccination±exposure) "we need focused and fewer tests, not more testing"
"Testing asymptomatic people is tricky ... major harms obscured"
@VPrasadMDMPH
9
19
127
Exciting update: 200th patient enrolled in the PRIMARY2 trial! Investigating PSMA PET scans' potential to improve diagnosis of prostate cancer and reduce unnecessary biopsies.
🙏
@ButeauJames
@drlouiseemmett
@DrDanielMoon
for driving
1
32
123
FDG PET/CT too often ignored: a game changer for advanced disease. Enhances disease site assessment, helps in🎯personalized theranostic treatments. Say goodbye to 'one-size-fits-all'! 💥
Nice review by Dr Sutherland:
3
39
123
Saw another patient this week misclassified as progression on DOTATATE PET/CT when the change was likely due to commencement of long-acting octreotide therapy. "Pseudoprogression" under-recognised phenomenon:
@globeseek
@marklewismd
@OncoThor
4
40
119
Wow! This is a huge honour and simply could not happen without the amazing teams at
@PeterMacCC
@gu_onc
@PeterMacRes
Huge Congratulations to
@DrMHofman
@PeterMacCC
for featuring in the 2024
@Australian
Top 250 Researchers
2
9
37
13
12
118
αlphaβet Trial: protocol now online
Will combining alpha and beta radiation lead to deeper & more durable response in prostate cancer?
recruiting
@PeterMacCC
@pros_tic
@AzadOncology
PhD YI:
@LouiseKosto
@ButeauJames
3
31
116
More Accurate Imaging Is Not Stage Migration: Time To Move from “Hubble” to “Webb” in Prostate Cancer
Identifying a serious confounder with CT/BS: false positive results
#PSMA
@declangmurphy
@stefanofanti4
@ProfKHerrmann
@EUplatinum
@APCCC_Lugano
7
31
114
Hot off the press. PSMA theranostics FDA approved: Lu-177 PSMA-617 (Pluvicto™) + Ga-68 kit (Locametz®) for PET imaging. First radioligand therapy for prostate cancer.
@PeterMacCC
ph2 spearheaded development. Prolongs survival & Improves quality of life
0
33
114
‘‘All that glitters is not gold!’’. Low volume metastatic disease on planar bone scans: high incidence of false positive results. Re-defining as benign on SPECT/CT or PSMA PET/CT is *not* stage migration or Will-Rogers effect, but simply more accurate.
4
32
109
Solitary rib lesion on
#PSMA
PET/CT in prostate cancer: be careful not to overcall. 98% benign. 6.5% false positive (median SUVmax 3).
@BJUIjournal
7
44
111
☢⚕️The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics
@JournalofNucMed
@SNM_MI
🙏
@CzerninJohannes
for the motivation
🕸
1
41
113
We grapple with "false positives" PSMA-PET bone mets in our MDTs frequently. Usually low-grade uptake on outside PET that we read as benign. New research from
@flavell_rob
@UCSFimaging
found 23% false+ve bone mets. SUVmax>4.1 predicted true positive.
4
60
111
Kinetics of PSMA uptake on PET post external beam radiotherapy: super interesting data from
#MasatoshiHotta
@CalaisJeremie
@ASCO
#GU22
. Lesion uptake decreases gradually and reaches lowest at 9-12 months. Prostate response slower than bone or LN.
Any thoughts
@_ShankarSiva
?
4
38
109
Lu-177-PSMA-617 vs. cabazitaxel: outcomes
PSA decline >=50%: 66 vs 37%
PFS: hazard ratio 0.63
12 month PFS: 19 vs 3%
ORR: 49 vs 24%
G3-4 AEs: 33 vs 53%
1
52
106
"Integration of radioligand therapy (RLT) with metastasis-directed therapy (MDT) might reduce progression, including polymetastatic progression, in the setting of oligorecurrent disease."
State-of-the-Art review by
@AmarUKishan
@_ShankarSiva
@CalaisJeremie
on role of
4
31
103
#LuTectomy
=one of our most exciting trials: Lu-177 PSMA-617 prior to prostatectomy. Recruitment on track despite COVID-19. Thanks
@MovemberAUS
@Novartis
& others. Protocol just published in Eur Urol Focus:
@gu_onc
@declangmurphy
@NattakornKnight
2
33
101
We followed up the patients in the 2019 highly cited first description of PSMA PET/CT findings in "non-metastatic prostate cancer" to see what happened with overall survival... Polymetastatic disease [≥5 metastasis] on PSMA PET/CT** was associated with shorter survival.
**
1
43
102
"When business leader Laurie Cox AO ran out of options to treat his advanced prostate cancer, fortune smiled on him. He was offered an experimental treatment that became life-extending."
@JillMargo1
@FinancialReview
@PeterMacCC
@PCF_Science
@pros_tic
6
33
98
ENZA-P Clinical Trials Protocol now online
@BJUIjournal
. Congrats
@drlouiseemmett
: leading the way in integrating PSMA PET as an imaging biomarker. 1st RCT of Lu-177-PSMA-617 + enzalutamide.
@ANZUPtrials
@MovemberAUS
@Novartis
@adacap_news
2
32
94
Wow! A great honour to receive on behalf of the
#ProPSMA
clinical trials team. Led by
@PeterMacCC
. 10-sites in all States, thanks to 300 patients. Amazing collaboration of nuc med, urology, rad onc, clinical trials staff.
@declangmurphy
@MovemberAUS
@PCFA
#ARTnet
@ANZUPtrials
Peter Mac has won
#ClinicalTrial
of the Year for the
#proPSMA
Study which found that a new molecular imaging technique is more accurate than conventional medical imaging, and recommends the scans be introduced into routine clinical practice. Read more:
6
24
105
9
14
95
Actinium-225 DOTATATE in
#neuroendocrinetumours
. Outcomes in 91 patients, 54 previously treated with Lutetium-177. Data looks promising: need investment in clinical trials. What does that look like? RCT of Lu-177 vs. Ac-225
@JournalofNucMed
@NECancerAus
1
30
93
Lu-177 PSMA-617 versus cabazitaxel: read our clinical trial protocol, now online in
@BJUIjournal
: . 200 patient randomised in 11 sites .... results 2020
@ANZUPtrials
@PCF_Science
@ANSTO
@adacap_news
3
54
91
Lutetium-177 PSMA Theranostics: Optimal Sequencing in 2023 and Future Outlook
#ASCODailyNews
@ASCO
Rapidly changing landscape: what do you think is next?
3
32
92
Fluciclovine (Axumin) vs PSMA PET-CT in biochemical recurrence: the results are in and there is a clear winner - 26% be 56% detection rate.
@gu_onc
proud to contribute this
@UCLATheranostic
research.
2
55
90
Almost all M0 pts with castration-resistant disease have PSMA-avid disease, around 50% M1. Great to contribute to this German-USA-Australian collaborative effort.
@PeterMacCC
#SUO18
2
44
91
Game changing ph3 Lu-PSMA-617 results. Proud to have led first prospective & ph2 trials
@PeterMacCC
@ANZUPtrials
. Looking forward to
@morr316
@ASCO
plenary & publication.
@pros_tic
3
26
88
#ASCO20
Metastasis-directicted ablative therapy using PSMA PET-MR/CT: ~80% were PSMA PET+ (all negative on conventional imaging). 60% had "response". Need ph3 trials: still experimental until then?
@_ShankarSiva
6
36
85
🔬Unraveling key factors influencing patient outcomes with PSMA radioligand therapy. Exploring resistance mechanisms. Dive into our review:
Wonderful collaboration with
@LouiseKostos
,
@AzadOncology
@ButeauJames
.
@TAMedOncol
2
39
86
#APCCC22
: highlighting the alarming false-positive (FP) rate of conventional imaging (CT and bone scan). In the ProPSMA study, when equivocal imaging findings were considered positive (sensitivity analysis) the FP rate was 23% vs 7% (CI vs PSMA). This is not stage migration.
2
42
87
📣 Just released! Joint
@EANM_NucMed
@SNM_MI
Lu-177 PSMA guidelines. Step forward in improving the standard of care for delivery of radioligand therapy.
@ProfKHerrmann
1
30
85
Awesome presentation by A/Prof Shahneen Sandhu
@Shahneen3
#ESMO21
with interim analysis of our
@PeterMacCC
led PRINCE trial: Lu-PSMA + pembroluzimab. mCRPC + PSMA/FDG selection. PSA≥50% 73%. RECIST ORR 78%. rPFS @ 24wks 65%. +G1-3 immune-related AEs vs Lu-PSMA alone.
1
32
84
Expanding theranostics beyond Lutetium-177 beta radiation to Terbium-161 and Lead-212
@PeterMacCC
@pros_tic
@PCF_Science
@LucFuric
@MHaskali
2
33
83
So much PSMA, imaging & therapy at this years
@APCCC_Lugano
... sneak preview of my talk: a picture tells a thousand words. REGISTER NOW!
@APCCC_Lugano
starts 9th Oct. Highlights include debate and voting on triplet therapy, PSMA staging, Lu PSMA therapy and HRD/PARPi therapy.
@Uromigos
@Silke_Gillessen
0
12
23
3
26
81
Updated outcomes of our n=50 Phase II Lu-177 PSMA-617 cohort: 64% (95%CI 50-77) achieved PSA≥50 response. In 14 patients who subsequently progressed and were given more Lu-PSMA, high response rates were also observed.
@PeterMacCC
@ASCO
#GU19
2
31
81
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Hot of the press in
@officialEANM
@stefanofanti4
@thomashopemd
@drlouiseemmett
0
37
81
Our Terbium-161 PSMA clinical trial reached full recruitment today, 10 months ahead of schedule. Incredible effort by
@PeterMacCC
and collaboration with
@Isotopia_il
and
@PCF_Science
#TeamScience
Contributing to 2 PhDs
@ButeauJames
@LouiseKostos
@AzadOncology
@pros_tic
0
22
82
#ProPSMA
54 month follow-up
#EAU23
"live"
@declangmurphy
✓ PSMA PET/CT N1 prognostic for failure - HR 2.1
✗ CT/BS not prognostic
= PSMA PET/CT findings significant. More and more longer term data supporting it's use.
Presented by
@veerukasi
Funding
@MovemberAUS
@PCFA
@pros_tic
1
26
80
A real honour and a testament to the collective efforts of our world-class team
@PeterMacCC
This accolade strengthens our commitment to advancing nuclear medicine, improving patient outcomes & continuing our journey of innovative healthcare solutions in Australia and beyond.
Pioneering new imaging technologies for cancer – a nuclear medicine physician‐scientist, his technologies are more accurate than standard imaging, with better outcomes compared to chemotherapy. Welcome Prof
@DrMHofman
as a new
#AAHMSFellow
.
@PeterMacCC
@Pros_TIC
3
8
36
12
16
81
Spectacular Aurora Australis last night 90 mins drive from Melbourne
#bellsbeach
#aurora
#nofilter
10 minute lapse
5
5
82
Our Tb-161 PSMA quantitative SPECT/CT first in human normal organ dosimetry presented
#EANM23
.
@Isotopia_il
@PCF_Science
@pros_tic
0
13
81
#LuCab
(Lu-177 PSMA-617 + cabazitaxel combo) up and running
@PeterMacCC
. First patient treated.
Support
@PCF_Science
@pros_tic
@Novartis
@ANSTO
Team
@AzadOncology
@LouiseKostos
@ButeauJames
0
24
81
What's new in oncology?
@UpToDate
updates for prostate cancer:
"For most males with PSMA-expressing mCRPC, we suggest 177-Lu [PSMA-617] rather than cabazitaxel after failure of ARPIs and docetaxel" citing
@ANZUPtrials
#TheraP
study.
2
19
79
Novel radiolabeled PARP PET imaging: striking images in breast cancer (ER+, TNBC and HER2+). Enables imaging of regional PARP-1 expression for the first time (= imaging tumour heterogeneity). May predict response to PARP inhibitors.
2
29
78
Honored to "lead"
@PCF_Science
#Tactical
:
Accelerated Theranostics platform using Lead-212 Targeted Alpha-particle Therapy to radically improve Prostate Cancer lethality and better understand resistance
@ProfKHerrmann
@CzerninJohannes
@thomashopemd
@felixfengmd
@KatharinaLueck1
CONGRATULATIONS to the
@PCFnews
2022 TACTICAL Award recipients!! This $30 million program will support 4 cross-disciplinary research teams working to develop 21st Century therapies for the most life-threatening forms of
#ProstateCancer
! 🥳🎉
5
14
62
5
14
78
Comparison of various radiotracers for therapy highlighting potential advantages of Lead-212 (Pb-212).
#AviralSingh
at
#ICRT22
1
13
77
Important study: more than 6 cycles of Lu-177 PSMA is both and safe and efficacious. For patients who benefited from initial cycles, there is an urgent need to enable global access to more cycles of effective treatment.
Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study | Journal of Nuclear Medicine
1
19
40
1
25
80
PSMA: The Target of the Decade, from Biochemical Recurrence to Widespread Adoption. Great honour to write this piece for
@SNM_MI
JNM 60th Anniversary Special. Nuclear medicine from 1960s to 2020 and beyond
0
18
76
Molecular imaging prognostic markers in men undergoing Lu-PSMA therapy for prostate cancer:
high volume of FDG-avid disease unfavourable. vs high PSMA-intensity favourable.
@gu_onc
@PeterMacCC
3
31
77
Ga-68 FAPI-04 compared to FDG PET/CT in a case of metastatic esophageal squamous cell carcinoma. SUVmax 21 vs. 13 + additional sites of disease visualised. Nice work from Fudan University Shanghai Cancer
Center.
0
29
76
Predict outcomes to Lu-PSMA in late-stage mCRPC with this tool: multicenter collaboration. Hot-of-the-press published in
@TheLancetOncol
outcomes of 270 pt.
Open access paper:
Web calculator:
2
38
75
Terbium-161 (161Tb) Quantitative SPECT/CT is here now!
@pj_physics
@ButeauJames
@EANM_NucMed
#VIOLET
0
22
75
The era of using metabolic tumour volume (MTV) to guide patient management has arrived. An actionable PET quantitative parameter that is superior to conventional IPI. .
@SFBarringtonKCL
@GeorgeMikhaeel
4
25
75
A long road began in 2014 seeing early data coming from Germany inspiring us to do a
@PeterMacCC
prospective trial of Lutetium-177 PSMA-617 in metastatic prostate cancer.
2
50
75
Excited to witness the future of PET/CT imaging in Bologna with
@stefanofanti4
. to see the first Total Body uEXPLORER PET/CT in Europe being installed. I would like a Birthday present this too!
Great to see the rest of the team inc.
@andrea_farolfi
2
7
75
Triplet therapy for prostate cancer:
@Prof_IanD
commentary on PEACE-1
@TheLancet
"It is not enough to talk about PEACE-1. One must believe in it. And it is not enough to believe in it. One must work at it."
@ANZUPtrials
@AlbertoBossial
1
17
74
Is F-18 DCFPyL equivalent or better than Ga-68 PSMA-11? A common question.
An uncommon question: is BPL equivalent to OSEM PET reconstruction?
The technical parameters that reconstruct your PET images matter just as much as choice of radiotracer.
Congrats
@NarjessAyati
on
3
18
75
🌟 Now accepting applications for 3 funded 2025 registrar/fellow nuclear medicine positions at Peter MacCallum Cancer Centre 🌟
Join our team and advance your career in a leading cancer research and treatment center!
If you're passionate about nuclear medicine and making a
2
17
74
Is PSMA PET/CT cost-effective for disease staging in men with high-risk prostate cancer? An analysis from the proPSMA randomised controlled study
@officialEANM
2020 Virtual Meeting Next Week
2
28
73